These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927 [TBL] [Abstract][Full Text] [Related]
7. [Cancer treatment response evaluation based on imaging modalities, such as computed tomography, magnetic resonance imaging and FDG-PET]. Endo M; Aramaki T; Moriguchi M; Sawada A; Asakura K; Bekku E Gan To Kagaku Ryoho; 2013 Mar; 40(3):294-8. PubMed ID: 23507590 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Mankoff DA; Eary JF; Link JM; Muzi M; Rajendran JG; Spence AM; Krohn KA Clin Cancer Res; 2007 Jun; 13(12):3460-9. PubMed ID: 17575208 [TBL] [Abstract][Full Text] [Related]
15. Impact of time-of-flight PET on quantification errors in MR imaging-based attenuation correction. Mehranian A; Zaidi H J Nucl Med; 2015 Apr; 56(4):635-41. PubMed ID: 25745090 [TBL] [Abstract][Full Text] [Related]
16. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Desar IM; van Herpen CM; van Laarhoven HW; Barentsz JO; Oyen WJ; van der Graaf WT Cancer Treat Rev; 2009 Jun; 35(4):309-21. PubMed ID: 19136215 [TBL] [Abstract][Full Text] [Related]